Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

Bibliography

• HOLMGREN L, O'REILLY MS, FOLKMAN J: Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. (1995) 1:149–153.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of pro- and anti-angiogenesis agents.
   Google Scholar
• ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev. Med. (1998) 49:407–424.
   PubMed Web of Science ®Google Scholar
• CHERRINGTON JM, STRAWN LM, SHAWVER LK: new paradigms for the treatment of cancer; the role of anti-angiogenic agents. Adv. Cancer. Res. (2000) 79:1–38.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, kdr, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. (1972) 175:409–419.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper in the field.
   Google Scholar
• BOEHM-VISWANATHAN T: Is angiogenesis inhibition the holy grail of cancer therapy? Carr: Opin. Oncol. (2000) 12:89–94.
   Google Scholar
• FERRARA N, HENZEL WJ: Pituitary follicular cells create a novel heparin-binding growth factor specific for endothelial cells. Biochem. Biophys. Res. Commun. (1989) 161:851–858.
   PubMed Web of Science ®Google Scholar
• HOUCK KA, FERRARA N, WINER J, CACHIANES G, LI B, LEUNG DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. MM. Endocrinol (1991) 5:1806–1814.
   PubMed Web of Science ®Google Scholar
• TERMAN BI, DOUGHER-VERMAZEN M, CARRION ME et al.: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. (1992) 187:1579–1586.
   PubMed Web of Science ®Google Scholar
• THOMAS KA: vascular endothelial growthfactor, a potent and selective angiogenic agent. Biol. Chem. (1996) 271:603–606.
   Web of Science ®Google Scholar
• KENDALL RL, THOMAS KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10705–10709.
   PubMed Web of Science ®Google Scholar
• SHALABY F, ROSSANT J, YAMAGUCHI TP et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 376:62–66.
   PubMed Web of Science ®Google Scholar
• LEE J, GRAY A, YUAN J, LUOH SM, AVRAHAM H, WOOD WI: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor F1t4. Proc. Nati Acad. Sci. USA (1996) 93:1988–1992.
   PubMed Web of Science ®Google Scholar
• DIAS S, CHOY M, ALITALO K, RAFII S: Vascular endothelial growth factor (VEGF-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival and resistance to chemotherapy. Blood(2002) 99:2179–2184.
   PubMed Web of Science ®Google Scholar
• FERRARA N: Molecular and biological properties of vascular endothelial growth factor. J. MM. Med. (1999) 77:527–543.
   PubMed Web of Science ®Google Scholar
• WITTE L, HICKLIN DJ, ZHU Z et al: Monoclonal antibodies targeting the VEGF receptor-2 (Flkl/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 17:155–161.
   PubMed Web of Science ®Google Scholar
• PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. (2000) 6:2094–2103.
   PubMed Web of Science ®Google Scholar
• DOUGHERVERMAZEN M, HULMES JD, BOHLEN P, TERMAN BI: Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem. Biophys. Res. Commun. (1994) 205:728–738.
   PubMed Web of Science ®Google Scholar
• KENDALL RL, RUTLEDGE RZ, MAO X, TEBBEN AJ, HUNGATE RW, THOMAS KA: Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. Biol. Chem. (1999) 274:6453–6460.
   Web of Science ®Google Scholar
• GIATROMANOLAKI A, SIVRIDIS E, ATHANASSOU N et al.: The angiogenic pathway 'vascular endothelial growth factor/ Flk-1 (KDR)-receptor' in rheumatoid arthritis and osteoarthritis. J. Path. (2001) 194:101–108.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, YEO KT et al: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment endothelial cells. Biochem. Biophys. Res. Commun. (1993) 193:631–638.
   PubMed Web of Science ®Google Scholar
• DETMAR M: The role of VEGF and thrombospondin in skin angiogenesis. Dermatol Sci. (2000) 24:S78–S84.
   PubMed Web of Science ®Google Scholar
• VAN BRUGGEN N, THIBODEAUX H, PALMER JT et al: VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Gin. Invest. (1999) 104:1613–1619.
   PubMed Web of Science ®Google Scholar
• LEVIN ER, ROSEN GF, CASSIDENTI DL et al.: Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. Clin. Invest. (1998) 102:1978–1985.
   Google Scholar
• SUN L, TRAN N, TANG F et al: Synthesis and biological evaluation of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Med. Chem. (1998) 41:2588–2603.
   Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, SMILICH BD et al.: Development of SU-5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15:29–41.
   PubMedGoogle Scholar
• FONG TAT, SHAWVER LK, SUN L et al: SU-5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• KRYSTAL G, HONSAWEK S, KIEWLICH D et al.: Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res. (2001) 61:3660–3668.
   PubMed Web of Science ®Google Scholar
• SUKBUNTHERNG J, CROPP G, HANNAH A, WAGNER GS, SHAWVER LK, ANTONIAN L: Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU-5416.1 Pharm. Pharmacol (2001) 53:1629–1636.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, SCHRECK RE, WEST DC et al.: The angiogenesis inhibitor SU-5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. (2000) 6:4858–4858.
   Google Scholar
• •Full cell data on SU-5416.
   Google Scholar
• TAN W, HAZNEDARJ, VANPETTEN M, IVENS I, ANTONIAN L, SUKBUNTHERNG J: Pharmacokinetics of SU-5416, an anti-angiogenesis agent, after single and multiple dosing in rats and dogs. American Association of Pharmaceutical Scientists Annual Meeting. Denver, CO, USA (2001).
   Google Scholar
• CROPP G, ROSEN L, MULAY M, LANGECKER P, HANNAH A: Pharmacokinetics and pharmacodynamics of SU-5416 in a phase I, dose escalating trial in patients with advanced malignancies. Proc. 743 Am. Soc. Clin. Oncol (1999) 18. Abstract 619.
   Google Scholar
• RAEISSI SD, WALTZ K, SUKBUNTHERNG J et al.: ha vitro model to elucidate the potential of the receptor tyrosine kinase (RTK) inhibitor SU-5416 to induce CYP1A1. Proc. Am. Assoc. Cancer Res. (2001) 42. Abstract 1020.
   Google Scholar
• ROSEN L, MULAY M, MAYERS A et a/.:Phase I dose-escalating trial of SU-5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (1999) 18. Abstract 618.
   Google Scholar
• O'DONNELL AE, TRIGO JM, BANERJI U et al.: Phase I trial of the VEGF inhibitor SU-5416, incorporating dynamic contrast MRI assessment of vascular permeability. Proc. Am. Soc. Gin. Oncol (2000) 19. Abstract 685.
   Google Scholar
• STOPECK A: Results of a phase I dose-escalating study of the anti-angiogenic agent SU-5416 in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (2000) 19. Abstract 802.
   Google Scholar
• MILES S, ARASTEH K, GIL P et al: A multicenter dose-escalating study of SU-5416 in AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol (2000) 19. Abstract 683.
   Google Scholar
• KINDLER HL, VOGELZANG NJ, CHIEN K et al: SU-5416 in malignant mesothelioma: University of Chicago Phase II consortium study. Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 1359.
   Google Scholar
• FIEDLER WM, TINNEFELD H, MENDET et al: A Phase II study with SU-5416 in patients with C-Kit positive AML. Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 1148.
   Google Scholar
• ROSEN PJ, KABBINAVAR F, FIGLIN RA et al.: A Phase I/II trial and pharmacokinetic (PK) study of SU-5416 in combination with paclitaxel/carboplatin. Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 389.
   Google Scholar
• OVERMOYER B, ROBERTSON K, PERSONS M et al.: A Phase I pharmacokinetic and pharmacodynamic study of SU-5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC). Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 391.
   Google Scholar
• MILLER LL, ELFRING GL, HANNAH AL, ALLRED R, SCIGALLA P, ROSEN LS: Efficacy results of a Phase I/II study of SU-5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (pts) from a Phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (IVICRC). Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 571.
   Google Scholar
• ROTHENBERG ML, BERLIN JD, CROPPGF et al: Phase I/II study of SU-5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol (2001) 20. Abstract 298.
   Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al: SU-6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
   PubMed Web of Science ®Google Scholar
• SMOLICH BD, YUEN HA, WEST KA, GILES FJ, ALBITAR M, CHERRINGTON JM: The antiangiogenic protein kinase inhibitors SU-5416 and SU-6668 inhibit the SCF receptor (C-Kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood (2001) 97:1413–1421.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, TSENG WW, DAVIS DW et al.: Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. (2001) 61:1464–1468.
   PubMed Web of Science ®Google Scholar
• SHAWVER LK, STRAWN LM, FONG TAT et al: SU-6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties. Proc. Am. Assoc. Cancer Res. (1999) 40. Abstract 4777.
   Google Scholar
• CHANDA SM, SUKBUNTHERNG J, YANG C et al: SU-5416 and SU-6668: comparative differences in toxicity profile in rats following intravenous administration. Proc. Am. Assoc. Cancer Res. (2000) 41. Abstract 4470.
   Google Scholar
• ROSEN LS, ROSEN PJ, KABBINAVAR F et al: Phase I experience with SU-6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc. Am. Soc. Gin. Oncol (2001) 20. Abstract 383.
   Google Scholar
• TRAXLER P, BOLD G, BUCHDUNGER E et al.: Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev (2001) 21:499–512.
   PubMed Web of Science ®Google Scholar
• •Good review of kinase inhibitor design, pharmacology and clinical issues.
   Google Scholar
• BOLD G, ALTMANN K-H, FREI J et al: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. (2000) 43:2310–2323.
   PubMed Web of Science ®Google Scholar
• WOOD JM, BOLD B, BUCHDUNGER E et al: PTK-787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2001) 60:2178–2189.
   Web of Science ®Google Scholar
• DREVS J, MROSS K, FUXIUS S et al.: APhase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF receptor-inhibitor PTK-787/ZK-222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc Am. Soc. Clin. Oncol (2001) 20. Abstract 398.
   Google Scholar
• DREVS J, HOFFMAN I, HUGENSCHMIDT H et al.: Effects of PTK-787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60:4819–4824.
   PubMed Web of Science ®Google Scholar
• SOLORZANO CC, BAKER CH, BRUNS CJ et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK-787/ZK-222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. (2001) 16:359–370.
   PubMed Web of Science ®Google Scholar
• YANO S, HERBST RS, SHINOHARA H et al.: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Can. Res. (2000) 6:957–965.
   PubMed Web of Science ®Google Scholar
• MORGAN B, BALL H, BUCHERT M et al.: Dynamic contrast enhanced magnetic resonance imaging as a surrogate marker of efficacy in a Phase I trial of a VEGF receptor tyrosine kinase inhibitor. Proc. Amer. Assoc. Cancer Res. (2001) 42. Abstract 587.
   Google Scholar
• OZAKI H, SEO M-S, OZARKI K et al: Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Path. (2000) 156:697–707.
   PubMed Web of Science ®Google Scholar
• FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Thar: (1999) 82:293–301.
   PubMed Web of Science ®Google Scholar
• PROPPER DJ, MCDONALD AC, MAN A et al.: Phase I and pharmacokinetic study of PKC-412, an inhibitor of protein kinase C. Oncol (2001) 19:1485–1492.
   Google Scholar
• SEO MS, KWAK N, OZARKI H et al: Dramatic inhibition of retinal and choroidal neovascularization of oral administration of a kinase inhibitor. Amer.' Path. (1999) 154:1743–1753.
   PubMed Web of Science ®Google Scholar
• HENNEQUIN LF, THOMAS AP, JOHNSTON C et al: Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. Med. Chem. (1999) 42:5369–5389.
   Web of Science ®Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al: ZD-4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. (2000) 60:970–975.
   PubMed Web of Science ®Google Scholar
• HENNEQUIN LF, STOKES ESE, THOMAS AP et al: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Med. Chem. (2002) 45:1300–1312.
   Web of Science ®Google Scholar
• HURWITZ HI, ECKHARDT SG, HOLDEN SN et al: A Phase I study of ZD-6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors. Proc. AACR-NCI-EORTC. Clio. Cancer Res. (2001) 7. Abstract 5.
   Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: Chronic and acute effects of ZD-6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumour xenografts. Proc. I I th NCI-EORTC-AACR Symp. Clio. Cancer Res. (2000) 6. Abstract 268.
   Google Scholar
• YANG R, THOMAS GR, BUNTING S et al.: Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.' Cardiovasc. Pharmacol (1996) 27:838–844.
   PubMed Web of Science ®Google Scholar
• KU DD, ZALESKI JK, LIU S, BROCK TA:Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. .1 Physic]. (1993) 265:586–592.
   Google Scholar